A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial

Temitope Oyedele; Rachel Park; Kelly Morales; Manish Jain; Lawrence Sher; Apinya Vutikullird; Abby Isaacs; Brett Jepson; Kathryn Shoemaker; Ann Marie Stanley; Joseph Lee; Cindy Handelsman; Stacey Cromer Berman; Lee-Jah Chang

doi:https://doi.org/10.1016/j.vaccine.2026.128304

A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial

Identifier:nobleid.org/w1/20260418/44B4B486

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/44B4B486.svg?ark=w1%2F20260418%2F44B4B486)](https://nobleid.org/work/w1/20260418/44B4B486)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial

Identifier:nobleid.org/w1/20260418/44B4B486

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/44B4B486.svg?ark=w1%2F20260418%2F44B4B486)](https://nobleid.org/work/w1/20260418/44B4B486)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work